Skip to content
The Policy VaultThe Policy Vault

Pemazyre (pemigatinib tablets − Incyte)Cigna

Myeloid/Lymphoid Neoplasms with eosinophilia and FGFR1 rearrangement

Initial criteria

  • Patient age ≥ 18 years
  • Patient has eosinophilia
  • Cancer has fibroblast growth factor receptor 1 (FGFR1) rearrangement as detected by an approved test

Approval duration

1 year